Arcus Biosciences Q2 Revenue Surges on Licensing Deals

Ticker: RCUS · Form: 10-Q · Filed: Aug 8, 2024 · CIK: 1724521

Sentiment: mixed

Topics: revenue-growth, licensing, net-loss, biotech

TL;DR

Arcus Bio's Q2 revenue nearly doubled to $40.8M on licensing, but still lost $100.4M.

AI Summary

Arcus Biosciences, Inc. reported its Q2 2024 results, with total revenue for the three months ended June 30, 2024, reaching $40.8 million, a significant increase from $19.7 million in the same period of 2023. This growth was primarily driven by license and development services revenue, which rose to $33.9 million from $12.8 million year-over-year. The company's net loss for the quarter was $100.4 million, compared to a net loss of $104.7 million in Q2 2023.

Why It Matters

The substantial increase in revenue suggests successful monetization of Arcus's drug development programs through partnerships, potentially improving its financial runway for ongoing research and clinical trials.

Risk Assessment

Risk Level: medium — While revenue growth is positive, the company continues to incur significant net losses, indicating ongoing reliance on funding for its drug development pipeline.

Key Numbers

Key Players & Entities

FAQ

What specific licensing agreements contributed to the increase in license and development services revenue?

The filing does not specify the individual licensing agreements that drove the revenue increase in Q2 2024, but notes the overall rise in license and development services revenue.

What is the company's cash burn rate based on the net loss and any disclosed cash flow information?

The filing reports a net loss of $100.4 million for Q2 2024, but does not directly provide a cash burn rate or detailed cash flow statement in the provided snippet.

What are the primary drivers for the ongoing net losses despite revenue growth?

The filing indicates significant operating expenses, likely related to research and development, are continuing to offset the revenue gains, leading to net losses.

Are there any upcoming clinical trial readouts or regulatory milestones mentioned in the report?

The provided snippet of the 10-Q filing does not contain information about upcoming clinical trial readouts or regulatory milestones.

What is the company's current cash and cash equivalents position as of June 30, 2024?

The provided text snippet does not include the company's cash and cash equivalents balance as of June 30, 2024.

Filing Stats: 4,732 words · 19 min read · ~16 pages · Grade level 15.2 · Accepted 2024-08-08 16:15:01

Key Financial Figures

Filing Documents

Financial Statements

Financial Statements 1 Condensed Consolidated Statements of Operations 1 Condensed Consolidated Statements of Comprehensive Loss 2 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Stockholders' Equity 4 Condensed Consolidated Statements of Cash Flows 5 Notes to Condensed Consolidated Financial Statements 6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 30 Item 4.

Controls and Procedures

Controls and Procedures 30 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 31 Item 1A.

Risk Factors

Risk Factors 31 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 57 Item 3. Defaults Upon Senior Securities 57 Item 4. Mine Safety Disclosures 57 Item 5. Other Information 58 Item 6. Exhibits 59

SIGNATURES

SIGNATURES 60 Table of Contents RISK FACTOR SUMMARY The following is a summary of the key risks and uncertainties that make an investment in our securities speculative and risky. The summary does not contain all of the information that may be important to you, and you should read this summary together with the more detailed description of the risks set forth under "Part II. Item 1A. Risk Factors" of the Quarterly Report. Risks Related to our Limited Operating History, Financial Position and Capital Requirements We have a history of operating losses, have never generated any revenue from product sales and anticipate that we will continue to incur significant losses for the foreseeable future. As a result, we may need to obtain additional funding to finance our operations. If we do not receive substantial capital when needed, we may be forced to restrict our operations or delay, reduce or eliminate our product development programs. Risks Related to the Discovery and Development of our Investigational Products Clinical drug development is a lengthy, expensive and uncertain process, if we are unable to develop, obtain regulatory approval for and commercialize our investigational products, or experience significant delays in doing so, our business will be materially harmed. The results of preclinical studies and early clinical trials, including interim data from our clinical studies that we announce or publish from time to time, are not always predictive of future results and could materially change due to audit and verification procedures or as more patient data become available. Competing treatments, clinical trials of competing investigational products, geopolitical instability and public health epidemics, each of which could result in significant delays and additional costs in our product development activities, or in the failure of such activities. Serious adverse events, undesirable side effects or other unexpected properties of our investigational pr

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements ARCUS BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In millions, except per share amounts) (unaudited) Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Revenues: License and development services revenue (Includes $ 25 , $ 19 , $ 156 and $ 36 from a related party) $ 28 $ 19 $ 163 $ 36 Other collaboration revenue (Includes $ 11 , $ 10 , $ 21 and $ 18 from a related party) 11 10 21 18 Total revenues 39 29 184 54 Operating expenses: Research and development (Includes $ 14 , $ 34 , $ 30 and $ 67 of net recoveries from a related party) 115 84 224 165 General and administrative 30 28 62 58 Impairment of long-lived assets (see Note 11, Leases) — — 20 — Total operating expenses 145 112 306 223 Loss from operations ( 106 ) ( 83 ) ( 122 ) ( 169 ) Non-operating income (expense): Interest and other income, net 13 9 26 18 Effective interest on liability for sale of future royalties — — ( 1 ) ( 1 ) Total non-operating income, net 13 9 25 17 Loss before income taxes ( 93 ) ( 74 ) ( 97 ) ( 152 ) Income tax expense — ( 1 ) — ( 3 ) Net loss $ ( 93 ) $ ( 75 ) $ ( 97 ) $ ( 155 ) Net loss per share: Basic and diluted $ ( 1.02 ) $ ( 1.04 ) $ ( 1.09 ) $ ( 2.13 ) Shares used to compute net loss per share: Basic and diluted 91.1 73.2 88.6 73.1 See accompanying notes. 1 Table of Contents ARCUS BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (In millions) (unaudited) Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Net loss $ ( 93 ) $ ( 75 ) $ ( 97 ) $ ( 155 ) Other comprehensive income (loss) — — ( 1 ) 3 Comprehensive loss $ ( 93 ) $ ( 75 ) $ ( 98 ) $ ( 152 ) See accompanying notes. 2 Table of Contents ARCUS BIOSCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In millions, except per share amounts) (unaudited) June 30, 2024 December 31, 2023 ASSETS Current assets: Cash and cash equivalents $

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing